ESMO 2023 | Combining ADC’s with other novel agents in the frontline treatment of urothelial carcinoma

Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, discusses the viability of combining antibody-drug conjugates (ADCs) as a paradigm for future drug development in urothelial carcinoma, covering ADCs as a frontline monotherapy, as well as in combination with other immunotherapies. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.